Affiliations: [a] Hematopathology Department, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, USA | [b] Department of Leukemia, M.D. Anderson Cancer Center, University of Texas, Houston, TX, USA | [c] Health Science Center, University of Texas, San Antonio, TX, USA
Correspondence:
[*]
Corresponding author: Dr. Maher Albitar, M.D., Quest Diagnostics, Nichols Institute, 33608 Ortega Highway, San Juan Capistrano, CA 92675, USA. Tel.: +1 949 728 4784; Fax: +1 949 728 4990; E-mail: maher.x.albitar@questdiagnostics.com.
Abstract: Roughly one-third of acute myeloid leukemia (AML) patients exhibit mutations in the nucleophosmin (NPM1) gene, and multiple studies have linked these mutations with a more favorable clinical outcome. We developed an assay for the detection of NPM1 mutations in peripheral blood plasma, and compared the results with clinical outcomes from a single institution. Analyzing plasma from previously untreated AML patients revealed NPM1 insertion mutations in 24 of 98 (24%) patients, with greater sensitivity than existing peripheral blood cell-based tests which showed positivity in only 22 of the 24 patients. Plasma testing allowed the detection of a novel 4 bp deletion in NPM1 in one patient. Analysis of clinical data corroborated previous data linking NPM1 mutations with better clinical outcome. These data underline the significance of NPM1 in the biology and clinical behavior of AML, and demonstrate the reliability and efficacy of plasma-based testing for NPM1 mutations.
